Live Chat

CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 74 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder.Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

Amgen live diagram

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

Seneste nyheder

Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies
Frances Wang 2024 Dec 19, 16:00

Gold performance and prediction: how high could gold price go?

Commodities
UK GDP
Dyogenes Diniz 2024 Dec 19, 16:00

Week ahead: Last full week of 2024 in the Financial Markets

Forex Indices
Frances Wang 2024 Dec 18, 16:00

Stock market today: Nasdaq Hits Record Highs as Tesla Achieves New Peaks

Stocks
Frances Wang 2024 Dec 18, 16:00

Dow Jones tumbles 1,100 points: why did the stock market go down today?

Stocks
Frances Wang 2024 Dec 18, 16:00

Super Micro Shares Drop 8% Following Nasdaq 100 Removal

Stocks

Info

Spread

1.83

Spread (%)

0.6972 %

Gearing

1:5

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market lukket

Mandag

14:31 - 20:59

Tirsdag

14:31-17:59

Torsdag

14:31-20:59

Fredag

14:31-20:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

141575438336

Aktier udestående

537532992

Indtjeningsdato (Næste)

1999-11-22

Udbytteprocent

2025-03-07

Ex-udbyttedato

2025-02-14

Forventet årlig udbyttesats

9.52

Forventet årlig udbytteprocent

0.0361

EPS

7.82

Få mere at vide om dette instrument

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre
Relaterede instrumenter
Trustpilot
Live Chat